Background An increased rate of brain atrophy is often observed in older subjects, in particular
those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, …

Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the
VITACOG trial, we showed that homocysteine‐lowering treatment with B vitamins slows the …

Aims Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart
failure and for death in patients with symptomatic heart failure. However, trials investigating …

Background: Increased brain atrophy rates are common in older people with cognitive
impairment, particularly in those who eventually convert to Alzheimer disease. Plasma …

A randomized trial (VITACOG) in people with mild cognitive impairment (MCI) found that B
vitamin treatment to lower homocysteine slowed the rate of cognitive and clinical decline. We …

Neuropeptides acting on pre- and postsynaptic receptors are coreleased with GABA by
interneurons including bistratified and O-LM cells, both expressing somatostatin but innervating …

Background: Methylmalonic acid (MMA) in plasma or serum is widely used for assessment
of vitamin B 12 status. However, data are sparse regarding factors, besides renal function, …

Objective Moderately elevated levels of plasma total homocysteine are associated with an
increased risk of developing Alzheimer's disease. We have tested whether baseline …

OBJECTIVE To investigate the safety and feasibility of 3 nonconsecutive days of intermittent
fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes. …

Aim To assess predictors of in‐hospital mortality in people with prediabetes and diabetes
hospitalized for COVID‐19 infection and to develop a risk score for identifying those at the …